Karyopharm to Present at Upcoming Healthcare Conferences

First Quarter Earnings Announcement Scheduled for May 7, 2014

        Print
| Source: Karyopharm Therapeutics

NATICK, Mass., May 5, 2014 (GLOBE NEWSWIRE) -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a clinical-stage pharmaceutical company focused on the discovery and development of novel first-in-class drugs directed against nuclear transport targets for the treatment of cancer and other major diseases, today announced that the company is scheduled to make the following presentations:

  • Deutsche Bank 39th Annual Healthcare Conference on Thursday, May 8, 2014 at 3:30 p.m. ET at The InterContinental Hotel in Boston, MA
     
  • Bank of America Merrill Lynch 2014 Health Care Conference on Tuesday, May 13, 2014 at 4:20 p.m. PT at the Encore at Wynn Hotel in Las Vegas, NV
     
  • Investor and analyst event, including a company presentation with a clinical data update, to be held on Monday, June 2, 2014 at 6:00pm CT in Chicago, IL. A webcast of the briefing can be accessed by visiting the Investors section of Karyopharm's website at www.karyopharm.com where a replay will be archived for 90 days follow the briefing.

Karyopharm also announced that it expects to release its financial results for the first quarter of 2014 and to provide highlights of its development programs on May 7, 2014. No conference call related to the earnings announcement is scheduled.

About Karyopharm

Karyopharm Therapeutics Inc. (Nasdaq:KPTI) is a clinical-stage pharmaceutical company focused on the discovery and development of novel first-in-class drugs directed against nuclear transport targets for the treatment of cancer and other major diseases. Karyopharm's Selective Inhibitors of Nuclear Export (SINE) compounds function by binding with and inhibiting the nuclear export protein XPO1 (or CRM1). The inhibition of XPO1 by Karyopharm's lead drug candidate, Selinexor (KPT-330), a first-in-class, oral SINE compound, leads to the accumulation of tumor suppressor proteins in the cell nucleus, which subsequently reinitiates and amplifies their tumor suppressor function. This is believed to lead to the selective induction of apoptosis in cancer cells, while largely sparing normal cells. SINE compounds have shown biological activity in models of cancer, autoimmune disease, certain viruses, and wound-healing. Karyopharm was founded by Dr. Sharon Shacham and is located in Natick, Massachusetts.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. Such forward-looking statements include the timing of the release of information regarding Karyopharm's reported earnings and development program. Any forward-looking statements contained in this press release speak only as of the date hereof, and Karyopharm expressly disclaims any obligation to update any forward-looking statements, whether as a result of new information, future events or otherwise.

Paul Brannelly

508-975-4820

Jennifer McNealey

917-392-3400